Article Details

Eledon asset shows optimistic biomarker activity in ALS trial - PharmaLive

Retrieved on: 2022-05-31 16:16:59

Tags for this article:

Click the tags to see associated articles and topics

Eledon asset shows optimistic biomarker activity in ALS trial - PharmaLive. View article details on hiswai:

Excerpt

Enter tegoprubart, an investigational humanized monoclonal antibody that inhibits CD40L. Eledon's 12-week trial studying 54 patients demonstrated ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up